Edition:
United Kingdom

Capricor Therapeutics Inc (CAPR.OQ)

CAPR.OQ on NASDAQ Stock Exchange Capital Market

1.33USD
26 Apr 2018
Change (% chg)

$-0.01 (-0.75%)
Prev Close
$1.34
Open
$1.33
Day's High
$1.38
Day's Low
$1.32
Volume
28,269
Avg. Vol
67,746
52-wk High
$4.25
52-wk Low
$0.63

Chart for

About

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the... (more)

Overall

Beta: -2.65
Market Cap(Mil.): $67.20
Shares Outstanding(Mil.): 23.50
Dividend: --
Yield (%): --

Financials

  CAPR.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -0.83 -- --
ROI: -645.84 1.58 14.38
ROE: -- 2.41 16.07

BRIEF-Capricor Q4 Earnings Per Share $0.42

* CAPRICOR PRESENTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND CORPORATE UPDATE

14 Mar 2018

BRIEF-Capricor Therapeutics Says ‍FDA Has Granted CAP-1002 RMAT Designation

* CAPRICOR THERAPEUTICS SAYS ‍FDA HAS GRANTED CAP-1002 REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION - SEC FILING Source text : (http://bit.ly/2s6RQ09) Further company coverage:

05 Feb 2018

BRIEF-Capricor Therapeutics Appoints Anthony Bergmann As CFO, Eff Jan 1, 2018 - SEC Filing

* CAPRICOR THERAPEUTICS INC SAYS HAS APPOINTED ANTHONY BERGMANN AS CHIEF FINANCIAL OFFICER, EFFECTIVE JANUARY 1, 2018 - SEC FILING

22 Dec 2017

BRIEF-Capricor Therapeutics Says FDA Cleared IND Application For CAP-1002

* CAPRICOR THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR CAP-1002

29 Nov 2017

BRIEF-Capricor Therapeutics reports Q3 loss per share $0.12

* Capricor Therapeutics reports third quarter 2017 financial results and provides update on duchenne muscular dystrophy development program

08 Nov 2017

Earnings vs. Estimates